Abstract 1566P
Background
Participation rate in lung cancer screening (LCS) programs is challenging. The ILYAD (Initiative LYonnaise pour l’Amorçage du Dépistage) study main objective is to assess whereas various communication methods may improve participation rate among a population of eligible staffs of Lyon University Hospital (LUH).
Methods
In a previous work, we assessed the number of eligible employees at LUH. 838 peoples among 26,954 staffs were found eligible to LCS according to current French guidelines. We designed an LCS program dedicated to staffs from LHU. We provided specific email address, phone number, and an online tool. We applied three communication methods for participants recruitment. We started with common displays (flyers, posters) and general emailing. Then, we involved managers of the departments identified with high-risk employees and occupational medicine. Finally, we used specially trained nurses to meet the employees in their daily routine.
Results
From September 2022 to May 2024, 144 participants were included, resulting in a participating rate of 17.2%. 85 (59%) were included during the first period (common displays and emails), 17 (12%) during the second (targeting high-risk), and 44 (30%) during the third (face to face meeting). Institutional general emailing appeared as the best way of recruitment. Surprisingly, face-to-face interaction were not very efficient, principally due to people lack of commitment afterward. During this first round of screening, one positive screening lead to the diagnosis of a stage IA adenocarcinoma. Moreover, we diagnosed 14 early COPD (group A and B). Coronary calcifications were identified in 15 cases. 70% participants contacted us through the online tool.
Conclusions
Despite a population of healthcare employees and different communication strategies tested, our results showed a low LCS participation rate. These results enhanced the fact that population adherence to LCS program will be a critical issue to address properly in order to improve screening efficiency.
Clinical trial identification
Sponsor code: 69HCL22_0466; NCT05452200 N° IDRCB: 2022-A01203-40 Approved by ethic committee CPP OUEST III: 23/06/2022.
Editorial acknowledgement
Legal entity responsible for the study
Hospices Civils de Lyon.
Funding
AstraZeneca Volition Transdiag.
Disclosure
S. Couraud: Financial Interests, Personal and Institutional, Funding, consulting fees: AstraZeneca, Amgen, Boehringer Ingelheim, MSD, Novartis, Sanofi, Roche, Pfizer, BMS; Financial Interests, Institutional, Funding: Chugai, Lilly, Takeda, Janssen, Celgene, Transdiag, Volition, Adene, BD Bioscience; Financial Interests, Personal, Other, consulting fees: Health event, MaaT Pharma, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10